Von willebrand factor antigen and factor XI activity levels as predictors of bleeding tendency in Israeli patients with von willebrand's disease

被引:4
|
作者
Brenner, B
Steinberg, T
Laor, A
Tavori, S
Tatarsky, I
Lanir, N
机构
[1] CARMEL HOSP,DEPT INTERNAL MED B,HAIFA,ISRAEL
[2] TECHNION ISRAEL INST TECHNOL,BRUCE RAPPAPORT FAC MED,IL-31096 HAIFA,ISRAEL
关键词
Von Willebrand's disease; factor XI deficiency; thrombocytopathy;
D O I
10.1177/107602969500100402
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previous preliminary data and case reports have suggested an association of von Willebrand's disease (vWD) with factor XI deficiency and platelet abnormalities. We have analyzed the prevalence of factor XI deficiency and thrombocytopathy in a cohort of Israeli patients with VWD. Decreased factor XI levels (<67 U/dl) were documented in 35 of 63 (56%) vWD subjects; factor XI levels were <30 U/dl in five of 60 (8%). A significant decline in ADP-induced platelet aggregation (<30% of control) was found in 48% of vWD patients. Likewise, epinephrine-induced aggregation was reduced in 41%, and collagen-induced aggregation was decreased in 7% of vWD patients. Logistic regression analysis showed that while Ivy bleeding time, ristocetin cofactor, and ristocetin-induced platelet aggregation did not predict bleeding, both von Willebrand factor antigen and factor XI activity levels predict bleeding in patients with vWD. These findings suggest that mild factor XI deficiency and thrombocytopathy are common in Israeli subjects with vWD and that associated factor XI deficiency can result in clinical bleeding in these patients.
引用
收藏
页码:260 / 264
页数:5
相关论文
共 50 条
  • [41] INHIBITION OF WILLEBRAND FACTOR IN VON WILLEBRAND DISEASE
    MARAGALL, S
    CASTILLO, R
    ORDINAS, A
    LIENDO, F
    RODRIGUEZ, M
    THROMBOSIS RESEARCH, 1979, 14 (2-3) : 495 - 500
  • [42] Screening for von Willebrand disease: contribution of an automated assay for von Willebrand factor activity
    Lasne, D.
    Dey, C.
    Dautzenberg, M. -D.
    Cherqaoui, Z.
    Monge, F.
    Aouba, A.
    Torchet, M. -F.
    Geloen, D.
    Landais, P.
    Rothschild, C.
    HAEMOPHILIA, 2012, 18 (03) : e158 - e163
  • [43] PHARMACOKINETIC MODELING OF THE VON WILLEBRAND FACTOR - FACTOR VIII INTERACTION IN PERIOPERATIVE VON WILLEBRAND DISEASE PATIENTS
    Bukkems, L. H.
    Heijdra, J.
    de Jager, N.
    Hazendonk, H.
    Fijnvandraat, K.
    Meijer, K.
    Eikenboom, J.
    Laros-van Gorkom, B.
    Leebeek, F.
    Cnossen, M.
    Mathot, R.
    HAEMOPHILIA, 2021, 27 : 147 - 147
  • [44] Quantification of von Willebrand Factor and von Willebrand Factor Propeptide in Patients with End Stage Renal Disease
    Davis, Rachael
    Bansal, Vinod
    Litinas, Evangelos
    Rahman, Saudur
    Hoppensteadt, Debra
    Conway, Brooke
    Fareed, Jawed
    FASEB JOURNAL, 2010, 24
  • [45] Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease
    Bukkems, Laura H.
    Heijdra, Jessica M.
    de Jager, Nico C. B.
    Hazendonk, Hendrika C. A. M.
    Fijnvandraat, Karin
    Meijer, Karina
    Eikenboom, Jeroen C. J.
    Laros-van Gorkom, Britta A. P.
    Leebeek, Frank W. G.
    Cnossen, Marjon H.
    Mathot, Ron A. A.
    BLOOD ADVANCES, 2021, 5 (05) : 1513 - 1522
  • [46] von Willebrand factor Ristocetin co-factor activity to von Willebrand factor antigen level ratio for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis
    Okubo, Noriyuki
    Sugawara, Shingo
    Fujiwara, Tohru
    Sakatsume, Ko
    Doman, Tsuyoshi
    Yamashita, Mihoko
    Goto, Kota
    Tateishi, Masaki
    Suzuki, Misako
    Shirakawa, Ryutaro
    Eura, Yuka
    Kokame, Koichi
    Hayakawa, Masaki
    Matsumoto, Masanori
    Kawate, Yasunori
    Miura, Mizuki
    Takiguchi, Hiroshi
    Soga, Yoshimitsu
    Shirai, Shinichi
    Ando, Kenji
    Arai, Yoshio
    Nakayoshi, Takaharu
    Fukumoto, Yoshihiro
    Takahama, Hiroyuki
    Yasuda, Satoshi
    Tamura, Toshihiro
    Watanabe, Shin
    Kimura, Takeshi
    Yaoita, Nobuhiro
    Shimokawa, Hiroaki
    Saiki, Yoshikatsu
    Kaikita, Koichi
    Tsujita, Kenichi
    Yoshii, Shinji
    Nakase, Hiroshi
    Fujimaki, Shin-ichi
    Horiuchi, Hisanori
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (01)
  • [47] Optimizing therapy with factor VIII von Willebrand factor concentrates in von Willebrand disease
    Federici, AB
    Mannucci, PM
    HAEMOPHILIA, 1998, 4 : 7 - 10
  • [48] Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia
    Molvarec, Attila
    Rigo, Janos, Jr.
    Boze, Tamas
    Derzsy, Zoltan
    Cervenak, Laszlo
    Mako, Veronika
    Gombos, Timea
    Udvardy, Miklos Laszlo
    Harsfalvi, Jolan
    Prohaszka, Zoltan
    THROMBOSIS AND HAEMOSTASIS, 2009, 101 (02) : 305 - 311
  • [49] Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A
    Stokol, T
    Trepanier, L
    Parry, BW
    Finnin, BC
    RESEARCH IN VETERINARY SCIENCE, 1997, 63 (01) : 23 - 27
  • [50] Factor XI deficiency associated with von Willebrand disease.
    Alvarez, MT
    Canales, M
    Villar, A
    Morado, M
    Sevilla, J
    Gago, J
    Sanjurjo, MJ
    Quintana, M
    Magallón, M
    Hdez-Navarro, F
    Ojeda, E
    BLOOD, 1998, 92 (10) : 556A - 556A